BOC and cancer: Particularly for ligand-dependent cancers, the complete characterization of the mechanism of ligand/receptor binding, including the role of the understudied pathway co-activators (CDO, BOC, and GAS1), may be fundamental to develop new inhibitors in the upcoming years, since there are no currently available pharmacological possibilities to inhibit the pathway at this upstream level.